Clinical Trial Results: Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating the early bactericidal activity, safety, and tolerability of oral GSK3036656 in combination regimens for rifampicin-susceptible…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• GSK3036656

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2026-06-17